1West of Scotland Coronary Prevention Study Group.Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS)[J].Circulation,1998,97:1 440～1 445.
2Downs JR, Clearfield M,Wies S,et al.Primary prevention of acute coronary events with average cholesterol levels:results of AFCAPS/TexCAPS:Air Force/Texas Coronary Atherosclerosis Provention Study[J].JAMA,1998,299:1 615～1 622.
3Sever PS,Dahlof B,Poulter NR,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA): a multicetre randomized controlled trial[J].The LANCET,2003,361:1 149～1 158.
4Candiavian Simvastatin Survival Group.Randomised trial of cholesterol lowering in 4 444 patients with coronary heart diseas:The Scandinavian Simvastatin Survival Study(4S)[J].Lancent,1994,344:1 383～1 389.
5Sacks FM,Preffer MA,Moyer LA,et al.The effect of prevastatin in coronary events after myocardial infarction in patients with average cholesterol levels[J].N Engl J Med,1996,335:1 001～1 009.
6The Long-term Intervention with Pravastionin in Ischemic Disease(LIPID)Study Group.Prevention of cardiovascular events and death with pravastation in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med,1998,339:1 349～1 357.
7Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5 963 people with diabetes:a randomized placebo-controlled trial[J].Lancet,2003,361:2 005～2 016.
8Shepherd J,Blauw GJ,Murphy MB,et al.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial[J].Lancet,2002,360:1 623～1 630.
9Kayilciglu M,Turkoglu C,Can L,et al.The combined use of pravastatin and thrombolytic agents in acute myocardial infarction :Clinical and angiographical results[J].J Am Coll Cardiol,2000,35(Suppl A):345A～346A.
10Den Hartog FR,Verheugt FWA.Early HMG-CoA reductase inhibition in ACS:preliminary data of the pravastation in acute ischemic syndromes(PAIS)study[J].Eur Heart J,1998,19(Abstract Suppl):2 802.
3Ong HT.The statin studies:from targeting hypercholesterolaemia to targeting the high-risk patient.QJM 2005;98(8):599-614
4Davidson MH.Clinical significance of statin pleiotropic effects-hypotheses versus evidence.Circulation 2005;111(18):2280-1
5Shepherd J,Cobbe SM,Ford I,et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group.N Engl J Med 1995;333(20):1301-7
6Waters D,Schwartz GG,Olsson AG.The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial:a new frontier for statins? Curr Control Trials Cardiovasc Med 2001;2(3):111-4
7Walter DH,Zeiher AM,Dimmeler S.Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells.Coron Artery Dis 2004;15(5):235-42
8Landmesser U,Bahlmann F,Mueller M,et al.Simvastatin versus ezetimibe:pleiotropic and lipid-lowering effects on endothelial function in humans.Circulation 2005;111(18):2356-63
9Dimmeler S,Aicher A,Vasa M,et al.HMG-CoA reductase inhibitors (statins)increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.J Clin Invest 2001;108(3):391-7
